Implantable Neurostimulators Market Is Projected To Grow Robustly By 2030 Implantable Neurostimulators

Rahul Nikade

Right Now

Implantable Neurostimulators Market Is Projected To Grow Robustly By 2030

Implantable Neurostimulators Industry

According to a recent report published by Grand View Research, Inc., the global market for implantable neurostimulators market is projected to reach a valuation of USD 9.87 billion by the year 2030. This market is expected to expand at a compound annual growth rate (CAGR) of 10.3% between 2025 and 2030. One of the primary factors contributing to this growth is the increasing prevalence of neurological disorders, coupled with a higher incidence of chronic pain and associated discomfort, which is creating a strong demand for neurostimulation solutions.

The growing number of patients diagnosed with neurological conditions such as Parkinson’s disease, epilepsy, essential tremor, chronic pain, and depression is significantly fueling the demand for implantable neurostimulators. As reported by the World Health Organization (WHO), approximately 50.0 million individuals around the globe were affected by epilepsy in 2020. Implantable neurostimulators are commonly utilized in the treatment of epileptic seizures, and hence, the rising number of epilepsy cases is anticipated to positively impact market growth over the coming years.

In addition, the increasing proportion of the global population that is aging is another important factor driving this market. Older adults are more prone to developing neurological disorders, and this demographic shift is expected to have a substantial impact on market demand. Data from the Centers for Disease Control and Prevention (CDC) reveals that Parkinson’s disease is predominantly diagnosed in individuals over the age of 60, with prevalence rates estimated to rise from 1.0% among those aged 60 and above to as high as 4% by the age of 80.

Furthermore, advancements in technology and the continuous launch of innovative products by key market players are anticipated to propel market expansion during the forecast period. A notable example of this is from September 2019, when Abbott received approval from the U.S. Food and Drug Administration (FDA) for its Proclaim XR recharge-free spinal cord stimulation (SCS) system, specifically designed for the management of chronic pain. Such technological advancements are likely to enhance treatment efficacy and patient compliance, further driving the adoption of implantable neurostimulators.

Curious about the Implantable Neurostimulators Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Implantable Neurostimulators Market Segments Highlights:

The spinal cord stimulators segment dominated the market with a revenue share of 39.7% in 2024, driven by their effectiveness in managing chronic pain conditions.
The pain management segment dominated the market with the largest revenue share in 2024, which can be attributed to the prevalence of chronic pain disorders globally.
The hospitals & Ambulatory Surgery Centers (ASC) segment dominated the market with the largest revenue share in 2024, driven by their role as primary providers of advanced medical treatments.
North America implantable neurostimulators market dominated the global market with a revenue share of 43.7% in 2024, which can be attributed to the high prevalence of chronic pain conditions and neurological disorders in the region.

Implantable Neurostimulators Market Report Segmentation

Grand View Research has segmented the global implantable neurostimulators market on the basis of product type, application, end use, and region:

Implantable Neurostimulators Product Type Outlook (Revenue, USD Billion, 2018 - 2030)